230 related articles for article (PubMed ID: 25786589)
1. Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.
Rochet N; Lindel K; Katayama S; Schubert K; Herfarth K; Schneeweiss A; Sohn C; Harms W; Debus J
Strahlenther Onkol; 2015 Jul; 191(7):582-9. PubMed ID: 25786589
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study.
Rochet N; Sterzing F; Jensen AD; Dinkel J; Herfarth KK; Schubert K; Eichbaum MH; Schneeweiss A; Sohn C; Debus J; Harms W
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1382-9. PubMed ID: 19628341
[TBL] [Abstract][Full Text] [Related]
3. Helical tomotherapy as a new treatment technique for whole abdominal irradiation.
Rochet N; Sterzing F; Jensen A; Dinkel J; Herfarth K; Schubert K; Eichbaum M; Schneeweiss A; Sohn C; Debus J; Harms W
Strahlenther Onkol; 2008 Mar; 184(3):145-9. PubMed ID: 18330510
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study.
Arians N; Kieser M; Benner L; Rochet N; Katayama S; Sterzing F; Herfarth K; Schubert K; Schröder L; Leitzen C; Schneeweiss A; Sohn C; Debus J; Lindel K
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):912-920. PubMed ID: 28870790
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol.
Rochet N; Jensen AD; Sterzing F; Munter MW; Eichbaum MH; Schneeweiss A; Sohn C; Debus J; Harms W
BMC Cancer; 2007 Dec; 7():227. PubMed ID: 18093313
[TBL] [Abstract][Full Text] [Related]
6. Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.
Rochet N; Kieser M; Sterzing F; Krause S; Lindel K; Harms W; Eichbaum MH; Schneeweiss A; Sohn C; Debus J
BMC Cancer; 2011 Jan; 11():41. PubMed ID: 21276234
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study.
Arians N; Kieser M; Benner L; Rochet N; Schröder L; Katayama S; Herfarth K; Schubert K; Schneeweiss A; Sohn C; Lindel K; Debus J
Radiat Oncol; 2019 Oct; 14(1):179. PubMed ID: 31639066
[TBL] [Abstract][Full Text] [Related]
8. Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes.
Rochet N; Kahn RS; Niemierko A; Delaney TF; Russell AH
Radiat Oncol; 2013 Oct; 8():236. PubMed ID: 24125168
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
Skírnisdóttir I; Lindborg K; Sorbe B
Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study.
Randall ME; Barrett RJ; Spirtos NM; Chalas E; Homesley HD; Lentz SL; Hanna M
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):139-47. PubMed ID: 12118543
[TBL] [Abstract][Full Text] [Related]
11. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
[TBL] [Abstract][Full Text] [Related]
12. Prospective phase I-II trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients.
Schwarz JK; Wahab S; Grigsby PW
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1258-63. PubMed ID: 20932657
[TBL] [Abstract][Full Text] [Related]
13. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes.
Firat S; Murray K; Erickson B
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):201-7. PubMed ID: 12909234
[TBL] [Abstract][Full Text] [Related]
14. Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy.
Skírnisdóttir I; Sorbe B
Int J Gynecol Cancer; 2007; 17(6):1231-7. PubMed ID: 17425681
[TBL] [Abstract][Full Text] [Related]
15. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
16. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
[TBL] [Abstract][Full Text] [Related]
17. Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy.
Desai NB; Kiess AP; Kollmeier MA; Abu-Rustum NR; Makker V; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Dec; 131(3):604-8. PubMed ID: 24055615
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors for survival of ovarian epithelial cancers: apropos of 287 cases].
Brun JL; Bouzigon E; Saurel J; Chêne G; Briex M; Brun G; Hocke C
Gynecol Obstet Fertil; 2000 Mar; 28(3):223-31. PubMed ID: 10786403
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.
Ardizzoni A; Tiseo M; Boni L; Di Maio M; Buffoni L; Belvedere O; Grossi F; D'Alessandro V; de Marinis F; Barbera S; Caroti C; Favaretto A; Cortinovis D; Morrica B; Tixi L; Ceschia T; Parisi S; Ricardi U; Grimaldi A; Loreggian L; Navarria P; Huber RM; Belani C; Brunsvig PF; Scagliotti GV; Scolaro T
Lung Cancer; 2016 Oct; 100():30-37. PubMed ID: 27597278
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
